If you have been reading about Certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-02. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
== Distribution == PfSPZ vaccines are cryopreserved and stored in LNVP freezers below -150 °C and distributed using dry vapor cryoshippers that also maintain temperature below -150 °C. Cryoshippers are self-contained mobile storage units that have hold times of ~14 to 28 days or more depending on model and packaging and are highly suited for last-mile transportation, particularly in Africa. Cryoshippers are used extensively in the livestock breeding, CAR-T and cellular therapies industries. LNVP distribution uses a simple hub-and-spoke model and cryoshippers stay at the immunization sites as temporary storage units that may be recharged with LN2. Advantages of the LNVP cold chain are a) independence from electricity, b) no requirement for fridges, freezers or refrigerated transport, c) no narrow temperature requirements, d) reduced chances for temperature deviations, e) no moving parts, and f) energy efficiency. LN2 is widely available, including in African countries, making LNVP distribution easier than the 2-8 °C and the dry ice and ultralow freezer-based cold chains of Ervebo (vs ebola) and certain SARS-CoV-2 vaccines. Modeling LNVP distribution also indicated costs would be no different per 3-dose regimen than the 2-8 °C cold chain for lyophilized vaccines.
India Today gave two-and-a-half stars out of five, stating "Barring a clichéd and predictable storyline, Darbar is strictly a film by a Rajinikanth fan for Thalaivar's fans". Sowmya Rajendran of The News Minute gave two-and-a-half stars out of five, and stated "Despite being a stale and predictable cop film, it's Rajinikanth's trademark swag that keeps the scenes alive". News18 gave three stars out of five, stating "Darbar is a terrific entertainer that has its shortcomings and dull moments, but Rajinikanth fans won't be disappointed". Manoj Kumar R. of The Indian Express wrote, "Murugadoss is among the handful of Tamil filmmakers who enjoy the reputation of making sensible and meaningful commercial films as opposed to churning out just brain-dead popcorn fare. And Darbar is the opposite of what we have come to expect of the director."
Population coverage: some countries have large surveillance networks that cover most of their population, while others use a smaller subset of hospitals and laboratories to generate data intended to be representative of the broader population. Sampling: EARS-Net data are only collected for invasive isolates (from blood or cerebrospinal fluid). These samples may not be representative of the members of this species that can colonize and infect humans, so resistance rates for other infections, such as urinary tract infections may vary. In some settings, laboratory microbiology work may only be performed in cases where initial antibiotic treatment has failed, leading to an overestimation of resistance rates. Laboratory routines and capacity: interpretation of minimum inhibitory concentration may vary across laboratories and countries, depending on current practice. Recommendations around converting minimum inhibitory concentration to resistance status also change over time, making comparison of resistance rates over time challenging.
atom. Somewhat unusually, this modification occurs in the Golgi apparatus, not in the endoplasmic reticulum. Similar to phosphorylated tyrosines, sulfated tyrosines are used for specific recognition, e.g., in chemokine receptors on the cell surface. As with phosphorylation, sulfation adds a negative charge to a previously neutral site. prenylation and palmitoylation
Attempting to quit "cold turkey" may result in neurological damage due to excitotoxicity, severe physical injuries received during convulsions, and even death resulting from arrhythmias during grande Mal seizures, paralleling death caused by delirium tremens.
Sources: en.wikipedia.org
LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1): LRP1 is involved in the endocytosis and degradation of various ligands, including AGEs. It is expressed in tissues such as the liver, vascular smooth muscle cells, and neurons. LRP1 functions by promoting the cellular uptake of AGE-modified proteins, thereby preventing their accumulation and reducing oxidative damage. The receptor also interacts with signaling pathways that regulate inflammation, making it an important factor in protecting against AGE-induced vascular and metabolic complications. MSR1 (Macrophage Scavenger Receptor 1): MSR1, also known as class A scavenger receptor, is expressed primarily on macrophages and plays a crucial role in the phagocytic uptake of AGEs. By recognizing and internalizing AGE-modified proteins, MSR1 helps reduce inflammation and cellular stress in tissues exposed to AGEs. This receptor is involved in activating pro-inflammatory signaling pathways, but it also contributes to tissue repair and the resolution of inflammation, helping maintain tissue homeostasis. FEEL-1/CLEC14A (Facultative Endothelial Lectin-1): FEEL-1, also known as CLEC14A, is a C-type lectin receptor expressed on endothelial cells. It binds AGEs and facilitates their clearance, thereby helping to maintain vascular health. The interaction of FEEL-1 with AGEs is thought to reduce endothelial cell activation and inflammation, contributing to the protection of blood vessels from AGE-induced damage and maintaining vascular integrity.
Incretins are a group of peptide metabolic hormones that decrease blood glucose levels. Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood-glucose–dependent mechanism. Incretins such as GLP-1 inhibit glucagon release from the alpha cells of the islets of Langerhans. In addition, they slow the rate of absorption of nutrients into the bloodstream by reducing gastric emptying and may reduce food intake. The two main peptides that fulfill criteria for an incretin are the intestinal peptide glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP, also known as: glucose-dependent insulinotropic polypeptide). GIP is produced and secreted into the blood by K cells located in the mucosa of the upper gastrointestinal tract's duodenum and upper jejunum while GLP1 is produced and secreted into the blood by L cells located in the mucosa of the lower gastrointestinal tracts small and large intestines. Short-chain fatty acids (primarily acetic, propionic, and butyric acids), which microganisms form in the intestines, bind to the FFAR2 and FFAR3 receptors on K cells and L cells to stimulate their respective production and secretion of GIP and GLP-1. Both GLP-1 and GIP are inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) and are members of the glucagon peptide superfamily.
=== Connection with Cancer treatment === hCTR1 is upregulated in various cancer types, and it's associated with prognosis in several solid tumors. Atox1 and ATP7B were found to be important for Pt-based drug resistance. hCTR1 plays a role in oncology, hCTR1 facilitates uptake of platinum-based chemotherapeutic agents, such as cisplatin. Yeast and mammalian cells lacking CTR1 were resistant to cisplatin, while cells overexpressing CTR1 accumulated more of the drug. Tumor cells when exposed to cisplatin often react by increased degradation of hCTR1, thereby they become drug-resistant while simultaneously exhibiting signs of perturbed copper homeostasis. Studies of Atox1 in cancer cells demonstrated that this copper chaperone is crucial for cancer cell proliferation and survival. Small molecules targeting Atox1 have been proved to effectively block Cu-trafficking. For that reason reduce cell proliferation in lung, leukemia, breast, head, and neck cancer cell lines by elevating cellular ROS levels and reducing cellular NADPH and GSH levels. In contrast, healthy cells were barely affected by these small molecules.
Another approach reduced interior temperature using a temperature-responsive hydrogel. Thermodynamic electricity generation: When combined with ions allows for heat dissipation for electronic devices and batteries and converting the heat exchange to an electrical charge. Water gel explosives Controlled release of agrochemicals (pesticides and fertilizer) Talin shock absorbing materials - protein-based hydrogels that can absorb supersonic impacts Computational tasks, including emergent memory.
Sources: en.wikipedia.org
For instance, 4-methylfentanyl, 4'-methylfentanyl and 4"-methylfentanyl are all known compounds, as are 3-methylthio-fentanyl and 3-methyl-thiofentanyl, all of which have varying potencies and pharmacokinetics. Confusion between different positional isomers is especially significant in the case of fentanyls because of the huge variation in potency between different members of the class. The weakest compounds such as benzylfentanyl are around the same potency as codeine (i.e. approximately 1/10th the potency of morphine), while the strongest compounds such as carfentanil and ohmefentanil can be over 10,000x more potent than morphine, meaning there is a 100,000-fold variation in potency between the strongest and weakest fentanyl derivatives. This means that two positional isomers with the same molecular weight, which may be difficult to tell apart without detailed chemical analysis, may be hundreds or even thousands of times different in pharmacological potency. Also the wide variety of substitutions that have been used on the basic fentanyl structure, each of which can either reduce or increase the potency, can be unpredictable when used in combination, so it may be impossible to estimate the likely potency of newly discovered analogues until pharmacological testing has been carried out.
In March 2015, Markie Pasternak of Green Bay, Wisconsin, was diagnosed as the youngest person to be living with HSAM. Born in 1994, Pasternak remembers every day of her life since February 2005. She was featured on 60 Minutes Australia in August 2016 with Rebecca Sharrock. In January 2016, painter and polymath Nima Veiseh was featured by the BBC for his use of hyperthymesia to create paintings that were said to only be producible with vast memories of art pieces, although a paper published in the journal Memory in 2022 claimed that having hyperthymesia does not increase one's creative thinking. Veiseh claimed to remember almost every day of his life since he was 15 years old, and that his ability to synthesise time and an "encyclopedic knowledge of the history of art" enabled him to create wholly unique visions on canvas. In March 2016 NPR examined further Veiseh's exploration of time and the human experience through art. In 2017, Australian Rebecca Sharrock of Brisbane became known as a person who claims to recall even circumstantial details of every day of her life from her 12th day of life onward. Discussing her hyperthymesia with BBC World Service, Sharrock revealed she was supporting two research projects – one with the University of Queensland and another with the University of California – to understand how a greater knowledge of hyperthymesia can support Alzheimer's disease research, particularly in repairing the degeneration of the hippocampus.
1993/2553) Hull and Holderness Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2554) Kent Ambulance National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2555) Kettering General Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2556) King's Mill Centre for Health Care Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2557) Leicestershire Ambulance and Paramedic Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2558) Leicestershire Mental Health Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2559) Lincoln Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2560) Northampton General Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2561) Norwich Community Health Partnership National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2562) Nottingham Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2563) Oxfordshire Ambulance National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2564) Oxfordshire Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2565) Oxfordshire Mental Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2566) Pilgrim Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2567) Plymouth Hospitals National Health Service Trust (Establishment) Order 1993 (S.I.
Okcuoglŭ, A.; Arcasoy, A.; Minnich, V.; Tarcon, Y.; Cin, S.; Yörükoğlu, O.; Demirag, B.; Renda, F. (August 1966). "Pica in Turkey. 1. The incidence and association with anemia". The American Journal of Clinical Nutrition. 19 (2): 125–131. doi:10.1093/ajcn/19.2.125. ISSN 0002-9165. PMID 5222998. Minnich, V.; Okçuoğlu, A.; Tarcon, Y.; Arcasoy, A.; Cin, S.; Yörükoğlu, O.; Renda, F.; Demirağ, B. (January 1968). "Pica in Turkey. II. Effect of clay upon iron absorption". The American Journal of Clinical Nutrition. 21 (1): 78–86. doi:10.1093/ajcn/21.1.78. ISSN 0002-9165. PMID 5237295. Glutathione synthesis
== Structure determination == Initial structures of eukaryotic ribosomes were determined by electron microscopy. First 3D structures were obtained at 30–40 Å resolution for yeast and mammalian ribosomes. Higher resolution structures of the yeast ribosome by cryo-electron microscopy allowed the identification of protein and RNA structural elements. Then structures at sub-nanometer resolution were obtained for complexes of ribosomes and factors involved in translation. After the determination of the first bacterial and archaeal ribosome structures at atomic resolution in the 1990s, it took another decade until in 2011, high resolution structures of eukaryotic ribosome were obtained by X-ray crystallography, mainly because of the difficulties in obtaining crystals of sufficient quality. The complete structure of a eukaryotic 40S ribosomal structure in Tetrahymena thermophila was published and described, as well as much about the 40S subunit's interaction with eIF1 during translation initiation. The eukaryotic 60S subunit structure was also determined from T. thermophila in complex with eIF6. The complete structure of the eukaryotic 80S ribosome from the yeast Saccharomyces cerevisiae was obtained by crystallography at 3.0 A resolution. These structures reveal the precise architecture of eukaryote-specific elements, their interaction with the universally conserved core, and all eukaryote-specific bridges between the two ribosomal subunits.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.